CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D007676: Kidney Failure, Chronic NIH

(Synonyms: Kidney Fa, Kidney Fai, Kidney Fail, Kidney Failur, Kidney Failure,, Kidney Failure,, Kidney Failure, C, Kidney Failure, Ch, Kidney Failure, Chron, Kidney Failure, Chroni, Kidney Failure, Chronic)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (10)


Name (Synonyms) Correlation
drug1326 Lazertinib Wiki 0.41
drug1454 Medically Tailored Meals Wiki 0.41
drug2803 dialysis Wiki 0.41
drug762 Diet tracking and survey Wiki 0.41
drug2867 less-frequency hemodialysis Wiki 0.41
drug809 EHR-based Clinician Jumpstart Wiki 0.41
drug1269 Itraconazole Wiki 0.29
drug2093 Rifampin Wiki 0.29
drug332 Best Practice Wiki 0.24
drug2527 Tocilizumab Wiki 0.08

Correlated MeSH Terms (19)


Name (Synonyms) Correlation
D017093 Liver Failure NIH 0.41
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.29
D014652 Vascular Diseases NIH 0.29
D016491 Peripheral Vascular Diseases NIH 0.29
D058729 Peripheral Arterial Disease NIH 0.24
D009362 Neoplasm Metastasis NIH 0.24
D051437 Renal Insufficiency, NIH 0.20
D003324 Coronary Artery Disease NIH 0.20
D008175 Lung Neoplasms NIH 0.20
D008103 Liver Cirrhosis, NIH 0.20
D009369 Neoplasms, NIH 0.18
D007674 Kidney Diseases NIH 0.18
D006333 Heart Failure NIH 0.15
D008173 Lung Diseases, Obstructive NIH 0.14
D017563 Lung Diseases, Interstitial NIH 0.13
D020521 Stroke NIH 0.13
D002908 Chronic Disease NIH 0.13
D008171 Lung Diseases, NIH 0.11
D007239 Infection NIH 0.02

Correlated HPO Terms (14)


Name (Synonyms) Correlation
HP:0001399 Hepatic failure HPO 0.41
HP:0006510 Chronic pulmonary obstruction HPO 0.29
HP:0001677 Coronary artery atherosclerosis HPO 0.20
HP:0000083 Renal insufficiency HPO 0.20
HP:0001395 Hepatic fibrosis HPO 0.20
HP:0100526 Neoplasm of the lung HPO 0.20
HP:0004950 Peripheral arterial stenosis HPO 0.18
HP:0000077 Abnormality of the kidney HPO 0.18
HP:0002664 Neoplasm HPO 0.18
HP:0001635 Congestive heart failure HPO 0.15
HP:0006536 Pulmonary obstruction HPO 0.14
HP:0006515 Interstitial pneumonitis HPO 0.13
HP:0001297 Stroke HPO 0.13
HP:0002088 Abnormal lung morphology HPO 0.11

There are 6 clinical trials

Clinical Trials


1 Using the Electronic Health Record to Identify and Promote Goals-of-Care Communication for Older Patients With Serious Illness

The objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over time, and across settings and providers. This study will examine the effect of the EHR-based intervention to improve quality of palliative care for patients over the age of 65 with chronic, life-limiting illness with a particular emphasis on Alzheimer's disease and related dementias (ADRD). The specific aims are: 1) to evaluate the effectiveness of a novel EHR-based (electronic health record) clinician Jumpstart guide, compared with usual care, for improving the quality of care; the primary outcome is documentation of a goals-of-care discussion during the hospitalization. Secondary outcomes focus on intensity of care: ICU use, ICU and hospital length of stay, costs of care during the hospitalization, and 30-day hospital readmissions; and 2) to conduct a mixed-methods evaluation of the implementation of the Jumpstart intervention, guided by the RE-AIM and CFIR frameworks for implementation science, incorporating quantitative assessments of effectiveness, implementation and maintenance and qualitative assessments of clinician perspectives on barriers and facilitators to future implementation and dissemination.

NCT04281784 Dementia Chronic Disease Neoplasm Metastasis Lung Neoplasm Pulmonary Disease, Chronic Obstructive Heart Failureļ¼ŒCongestive Liver Cirrhosis Kidney Failure, Chronic Lung Diseases, Interstitial Peripheral Vascular Disease Diabetes With End Organ Injury Palliative Care, Patient Care Health Care Quality, Access, and Evaluation Patient Care Inpatients Health Communication Patient Care Planning Behavioral: EHR-based Clinician Jumpstart
MeSH:Neoplasm Metastasis Lung Neoplasms Liver Cirrhosis Lung Diseases Pulmonary Disease, Chronic Obstructive Lung Diseases, Interstitial Renal Insufficiency Kidney Failure, Chronic Heart Failure Vascular Diseases Peripheral Vascular Diseases Peripheral Arterial Disease Chronic Disease Neoplasms
HPO:Abnormal lung morphology Chronic pulmonary obstruction Cirrhosis Congestive heart failure Hepatic fibrosis Interstitial pneumonitis Interstitial pulmonary abnormality Left ventricular dysfunction Neoplasm Neoplasm of the lung Peripheral arterial stenosis Renal insufficiency Right ventricular failure

Primary Outcomes

Description: The primary outcome is the proportion of patients who have a goals-of-care (GOC) discussion that has been documented in the EHR in the period between randomization and 30 days following randomization The proportion is the number of patients with GOC documentation over the number of patients in each study arm. Documentation of goals-of-care discussions will be evaluated using our NLP/ML methods. Study staff will manually review and compare findings using a randomly-selected sample of charts using our standard EHR abstraction methods; manual chart abstraction will be the gold standard.

Measure: EHR documentation of Goals of Care discussions

Time: Assessed for the period between randomization and 30 days following randomization

Secondary Outcomes

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU admissions during the patient's (index) hospital stay will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care/ICU use: ICU admissions

Time: Assessed for the period between randomization and 30 days following randomization

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the ICU during their (index) hospital stay will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care/ICU use: ICU length of stay

Time: Assessed for the period between randomization and 30 days following randomization

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the hospital during that (index) hospital stay will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care/Hospital use: Hospital length of stay

Time: Assessed for the period between randomization and 30 days following randomization

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of hospital readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care: Hospital Readmissions 30 days

Time: Assessed for the period between randomization and 30 days following randomization

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care: ICU Readmissions 30 days

Time: Assessed for the period between randomization and 30 days following randomization

Description: Costs for intervention vs. control will be reported in US dollars and identified from UW Medicine administrative financial databases. Costs will be reported for total hospital costs and disaggregated costs (direct-variable, direct fixed, indirect costs). Direct-variable costs will include supply and drug costs. Direct-fixed costs will include labor, clinical department administration, and overhead fees. Indirect costs represent services provided by cost centers not directly linked to patient care such as information technology and environmental services. Costs for ED (emergency department) days and ICU days will be similarly assessed.

Measure: Intensity of care: Healthcare costs

Time: 1 and 3 months after randomization

Description: From Washington State death certificates.

Measure: All-cause mortality at 1 year (safety outcome)

Time: 1 year after randomization

Other Outcomes

Description: Qualitative interviews after individual participation. Interviews will be guided by the RE-AIM and Consolidated Framework for Implementation Research (CFIR) to explore the factors associated with implementation (e.g., reach, maintenance, feasibility, inner and outer settings, individuals, and processes of care.) Individual constructs within these domains were chosen to fit this specific intervention and context.

Measure: Key Implementation Factors

Time: 3 months after randomization

2 Meals MATTER: A Randomized Controlled Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge

The purpose of this study is to determine if medically tailored meals provided for either 2 weeks or 4 weeks (1 meal per day) to a Kaiser Permanente Colorado (KPCO) member after hospital discharge will improve their health. Medically tailored meals (MTM) are meals that are approved by a dietitian and shown to help people with certain health conditions.

NCT04351880 Heart Failure Copd Liver Failure Covid19 Diabetes Mellitus Cancer End Stage Renal Disease Other: Medically Tailored Meals
MeSH:Liver Failure Kidney Failure, Chronic
HPO:Hepatic failure

Primary Outcomes

Description: Measured through the Hospital Anxiety and Depression Scale. 0 = Minimum. 21 = Maximum. Higher score is worse outcome.

Measure: Anxiety and Depression measured through the Hospital Anxiety and Depression Scale

Time: A change in score from baseline to 60 days

Secondary Outcomes

Description: Measured through the Katz Activities of Daily Living. Minimum = 0, Maximum = 6. Higher score is better outcome.

Measure: Functional Status measured through the Katz Activities of Daily Living Scale

Time: A change in score from baseline to 60 days

Description: Measured through time of discharge through re-hospitalization or Emergency Department visit

Measure: Re-hospitalization and Emergency Department Visits

Time: 60 days from hospital discharge

3 Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial

This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.

NCT04361552 Cerebrovascular Accident Chronic Obstructive Pulmonary Disease Chronic Renal Failure Coronary Artery Disease Diabetes Mellitus Malignant Neoplasm SARS Coronavirus 2 Infection Other: Best Practice Biological: Tocilizumab
MeSH:Infection Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Stroke Kidney Failure, Chronic Coronary Artery Disease Neoplasms
HPO:Chronic pulmonary obstruction Coronary artery atherosclerosis Neoplasm Pulmonary obstruction Stroke

Primary Outcomes

Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.

Measure: 7-day length of invasive mechanical ventilation (MV)

Time: Up to 7 days

Description: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: 30-day mortality rate

Time: Up to 30-day after randomization

Secondary Outcomes

Description: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of intensive care (ICU) transfer

Time: Up to 2 years

Description: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of invasive mechanical ventilation

Time: Up to 2 years

Description: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of tracheostomy

Time: Up to 2 years

Description: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test

Measure: Length of ICU stay

Time: Up to 2 years

Measure: Length of hospital stay

Time: Up 2 years

4 Reduced Frequency Hemodialysis in Prevalent Patients Due to the Coronavirus Disease

Facing the unusual situation imposed by the coronavirus disease, the aim of this study is to evaluate the risk and effects of less frequent hemodialysis on prevalent patients

NCT04374058 End Stage Renal Disease Other: less-frequency hemodialysis
MeSH:Kidney Failure, Chronic

Primary Outcomes

Description: Time to all-cause and cardiovascular death

Measure: Mortality

Time: From date of beginning of the study until the date of death assessed up to 52 weeks

Secondary Outcomes

Description: Time variation of the biological parameters mentioned in the title. Repeated measurements of laboratory variables will be averaged into patient quarterly means to minimize measurement variability.

Measure: Anemia, Nutrition, Adequation of dialysis, total ultrafiltration, ultrafiltration rate,

Time: From date of beginning of the study assessed up to 52 weeks

Description: Time to first hospitalization of any cause

Measure: Hospitalization

Time: From date of beginning of the study until the date of first hospitalization assessed up to 52 weeks

Description: Time to first endovascular or quirurgical intervention of the vascular access utilized at the start of the study

Measure: Vascular Access

Time: From date of beginning of the study until the date of first intervention assessed up to 52 weeks

5 A Comparative Study of Symptom-driven Surveillance vs. Cross-sectional Serological Screening of SARS-CoV-2 Infection of Patients With End-stage Kidney Disease Receiving Renal Replacement Therapy

Starting in late 2019, the world is facing a pandemic with the SARS-CoV-2 virus. Patients with end-stage kidney disease and on treatment with renal replacement therapy are high risk patients, as they are unable to maximize social distancing. We plan to gather epidemiological data using two different diagnostic approaches. We will compare a symptom-driven screening, in combination with a nasopharyngeal swab plus computed tomography (clinical approach) against serological surveillance.

NCT04378686 SARS-CoV 2 End Stage Renal Failure on Dialysis Other: dialysis
MeSH:Kidney Failure, Chronic

Primary Outcomes

Description: serology to test for IgG and IgM antibodies against SARS-CoV-2

Measure: Antibodies against SARS-CoV-2

Time: one year

6 The Impact of Coronavirus (COVID-19) Restrictions on Wellbeing, Quality of Life and Physical Activity in People With End-stage Renal Disease, Currently Dialysing In-centre Versus at Home in the UK and Their Experience of Telemedicine

To understand the impact of COVID-19 restrictions on the wellbeing, quality of life and physical activity of people with end-stage renal disease, currently dialysing in-centre versus at home in the UK and their experience of telemedicine.

NCT04422873 End Stage Renal Disease Sars-CoV2
MeSH:Kidney Diseases Kidney Failure, Chronic
HPO:Abnormality of the kidney Nephropathy

Primary Outcomes

Description: Participants will be asked during a qualitative interview about the effect of COVID-19 restrictions on their; well-being, quality of life and physical activity and sedentary behaviours

Measure: Qualitative assessment of the effect of COVID-19 restrictions on patients' well-being, quality of life and physical activity and sedentary behaviours

Time: Day 1

Secondary Outcomes

Description: Participants will be asked during a qualitative interview about their perceptions and experiences of telemedicine

Measure: Thematic analysis of qualitative interview exploring patients' experiences of telemedicine during the COVID-19 restrictions in the UK

Time: Day 1


HPO Nodes